Standout Papers

Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor recep... 2020 2026 2022 2024347
  1. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1 (2020)
    Fabrice André, Eva Ciruelos et al. Annals of Oncology

Citation Impact

1 from Science/Nature 50 standout
Sub-graph 1 of 24

Citing Papers

PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment
2024 Standout
Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy
2024 Standout
1 intermediate paper

Works of Mathilde Kaper being referenced

Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1
2020 Standout
Preliminary findings from part 1 of COMBI-i: A phase III study of anti–PD-1 antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma.
2018

Author Peers

Author Molecular Biology Urology Oncology PRM Last Decade Papers Cites
Mathilde Kaper 259 195 234 233 16 851
Glen Blake 281 4 158 8 5 633
H Solomon 26 148 5 5 5 455
Salvatore Dinardo 6 6 35 630
Christopher Burlak 117 2 32 12 20 436
Alice S. Y. Chow 26 602

All Works

Loading papers...

Rankless by CCL
2026